Table 5.
Anti-mutagenic potential of AFB1 a-spiked fractions obtained from thin layer chromatography fractionation of fraction RB213 (R f = 0.68–1.00) from TLC 2 (averageb TA100 and TA98 revertants/plate, with S9).
| Extract fractionc | Fraction dilutionc | |||
|---|---|---|---|---|
| 1 × 100 | 1 × 10−1 | 1 × 10−2 | 1 × 10−3 | |
| TA98 | ||||
| RB2132 (R f = 0.85–0.94) | 79 ± 11 | 245 ± 25 | 409 ± 29 | 502 ± 28 |
| RB2133 (R f = 0.94–1.00) | 399 ± 35 | 435 ± 49 | 489 ± 41 | 576 ± 21 |
|
| ||||
| TA100 | ||||
| RB2132 (R f = 0.85–0.94) | 178 ± 13 | 389 ± 41 | 603 ± 59 | 918 ± 28 |
| RB2133 (R f = 0.94–1.00) | 499 ± 35 | 829 ± 63 | 1237 ± 128 | 1465 ± 121 |
aAFB1 (used as positive control) tested at 500 ng/plate induced 491 ± 33 and 1283 ± 78 revertants/plate for TA98 and TA100, respectively. Spontaneous revertants were 54 ± 3 and 128 ± 11 for TA98 and TA100, respectively.
bValues are means of three replicates ± SEM.
cExtracts were diluted and spiked with enough toxin to yield 500 ng of pure AFB1/plate.